# A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

> **NCT01317927** · PHASE1 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 27 (actual)

## Conditions studied

- Solid Tumor
- Hematological Malignancy

## Interventions

- **DRUG:** Belinostat, Warfarin

## Key facts

- **NCT ID:** NCT01317927
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2015-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01317927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01317927, "A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01317927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*